| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNISA996390986803316 |
|
|
Autore |
Savile Henry, Sir, <1549-1622.> |
|
|
Titolo |
Praelectiones tresdecim in principium Elementorum Euclidis [[electronic resource] ] : Oxonii habitæ M.DC.XX |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Oxonii, : Excudebant Iohannes Lichfield, & Iacobus Short, 1621 |
|
|
|
|
|
|
|
Descrizione fisica |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
By Sir Henry Savile, whose name appears on A2r. |
Title page bears Oxford device. Variant: lacks device. |
Reproduction of the original in the British Library. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910780603203321 |
|
|
Titolo |
Pharmaceutical dosage forms Tablets |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
New York : , : Informa Healthcare USA, , 2008 |
|
|
|
|
|
|
|
ISBN |
|
0-429-19115-4 |
1-4200-2029-3 |
|
|
|
|
|
|
|
|
Edizione |
[3rd ed. /] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (550 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
AugsburgerLarry L |
HoagStephen W |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Tablets (Medicine) |
Drugs - Dosage forms |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Front Cover; Foreword; Preface; Contents; Contributors; Chapter 1. Mass Transfer from Solid Oral Dosage Forms; Chapter 2. Approaches for Improving Bioavailability of Poorly Soluble Drugs; Chapter 3. Aims and Objectives and of Experimental Design and Optimization in Formulation and Process Development; Chapter 4. Knowledge-based Systems and Other AI Applications for Tableting; Chapter 5. Direct Compression and the Role of Filler-binders; Chapter 6. Disintegrants in Tableting; Chapter 7. Lubricants, Glidants, and Antiadherents; Chapter 8. Surfactants and Colors in Tablets |
Chapter 9. Orally Disintegrating Tablets and Related Tablet FormulationsChapter 10. Formulation Challenges: Multiple Vitamin and Mineral Dosage Forms; Chapter 11. Botanicals and Their Formulation into Oral Solid Dosage Forms; Chapter 12. Formulation of Specialty Tablets for Slow Oral Dissolution; Chapter 13. Formulation and Design of Veterinary Tablets; Chapter 14. Swellable and Rigid Matrices: Controlled Release Matrices with Cellulose Ethers; Chapter 15. Carrageenans in Solid Dosage Form Design; Chapter 16. Osmotic Systems; Chapter 17. Tableting of Multiparticulate Modified Release Systems |
Back Cover |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
<b><i>Pharmaceutical Dosage Forms: Tablets, Third |
|
|
|
|
|
|
|
|
|
|
|
|
|
Edition</i></b>is acomprehensive treatment of the design, formulation, manufacture, and evaluation of the tablet dosage form. The ultimate goal of drug product development is to design a system that maximizes the therapeutic potential of the drug substance and facilitates its access to patients; <b><i>Volume 2</i></b> focuses on the rational design, and formulation of a tablet and includes chapters with practical illustrations and formulation examples. |
|
|
|
|
|
|
3. |
Record Nr. |
UNINA9910817344203321 |
|
|
Autore |
Eyjolfsson Reynir |
|
|
Titolo |
Design and manufacture of pharmaceutical tablets / / Reynir Eyjolfsson |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
London, England : , : AP, , 2015 |
|
©2015 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (68 p.) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Drugs - Dosage forms |
Pharmaceutical industry |
Tablets (Medicine) |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references at the end of each chapters and index. |
|
|
|
|
|
|
|
|
Nota di contenuto |
|
Cover; Title Page; Copyright Page; Dedication; Contents; Preface; Abbreviations; Chapter One - Introduction; 1.1 - General considerations; 1.2 - Particle sizes; 1.3 - Excipients; 1.3.1 - Ac-Di-Sol SD-711; 1.3.2 - Aerosil 200; 1.3.3 - Avicel PH-102; 1.3.4 - Compactrol; 1.3.5 - Corn starch; 1.3.6 - Di-Tab; 1.3.7 - Eudragit RS PO; 1.3.8 - Magnesium stearate 5712; 1.3.9 - Mannitol 60; 1.3.10 - Methocel K4M Premium; 1.3.11 - Methocel K100M Premium; 1.3.12 - Methocel K100LV Premium; 1.3.13 - Pharmatose 150M; 1.3.14 - Polyplasdone XL-10; 1.3.15 - Povidone; 1.3.16 - Primojel; 1.3.17 - Pruv |
1.3.18 - Sodium bicarbonate1.3.19 - Starch 1500; 1.3.20 - Stearic acid 2236; 1.3.21 - Sterotex K; 1.3.22 - Tablettose 80; 1.3.23 - Talc; 1.4 - |
|
|
|
|
|
|
|
|
|
|
|
Equipment; 1.5 - Mixing of pharmaceutical powders; 1.6 - Design of experiments; 1.6.1 - Introduction to statistical design of experiments - the two-level factorial; 1.6.1.1 - Introduction; 1.6.1.2 - Designed experiments; 1.6.1.3 - Basic considerations; 1.6.1.4 - Two-level factorials; 1.6.1.5 - Two-level fractional factorials; 1.6.2 - Response surface methodology (RSM); 1.6.2.1 - Introduction; 1.6.2.2 - RSM and a sieving process variable study |
1.6.2.3 - RSM investigation of the properties of a three-component tablet formulationReferences; Chapter two - Conventional-Release (CR) Tablets; 2.1 - Low-dose tablet by direct compression (DC); 2.1.1 - Properties of active pharmaceutical ingredient (API); 2.1.2 - Design; 2.1.3 - Manufacturing method; 2.1.4 - Remarks; 2.2 - High-dose tablet by direct compression; 2.2.1 - Properties of active pharmaceutical ingredient; 2.2.2 - Design; 2.2.3 - Manufacturing method; 2.2.4 - Remarks; 2.3 - Low-solubility API, low-dose tablet by wet granulation (WG) |
2.3.1 - Properties of active pharmaceutical ingredient2.3.2 - Design; 2.3.3 - Manufacturing method; 2.3.4 - Remarks; 2.4 - Soluble API, low-dose tablet by wet granulation; 2.4.1 - Properties of active pharmaceutical ingredient; 2.4.2 - Design; 2.4.3 - Manufacturing method; 2.4.4 - Remarks; 2.5 - Low-solubility API, high-dose tablet by wet granulation; 2.5.1 - Properties of active pharmaceutical ingredient; 2.5.2 - Design; 2.5.3 - Manufacturing method; 2.5.4 - Remarks; 2.6 - Soluble API, high-dose tablet by wet granulation; 2.6.1 - Properties of active pharmaceutical ingredient; 2.6.2 - Design |
2.6.3 - Manufacturing method2.6.4 - Remarks; References; Chapter three - Slow-Release (SR) Tablets; 3.1 - Slow-release tablet using a lipophilic release control agent; 3.1.1 - Properties of active pharmaceutical ingredient (API); 3.1.2 - Design; 3.1.3 - Manufacturing method; 3.1.4 - Remarks; 3.2 - Slow-release tablet using Eudragit and Methocel as release control agents; 3.2.1 - Properties of active pharmaceutical ingredient; 3.2.2 - Design; 3.2.3 - Manufacturing method; 3.2.4 - Remarks; 3.3 - Slow-release tablet using a mixture of Methocels as release control agent |
3.3.1 - Properties of active pharmaceutical ingredient |
|
|
|
|
|
|
Sommario/riassunto |
|
Design and Manufacture of Pharmaceutical Tablets offers real world solutions and outcomes of formulation and processing challenges of pharmaceutical tablets. This book includes numerous practical examples related to actual formulations that have been validated and marketed and covers important data in the areas of stability, dissolution, bioavailibity and processing. It provides important background and theoretical information on design and manufacturing and includes a full section dedicated to design experimental methodology and statistics. In addition, this book offers a a general discuss |
|
|
|
|
|
|
|
| |